Large-Scale Immunomagnetic Selection of CD14+Monocytes to Generate Dendritic Cells for Cancer Immunotherapy: A Phase I Study
- 1 October 2003
- journal article
- clinical trial
- Published by Mary Ann Liebert Inc in Journal of Hematotherapy & Stem Cell Research
- Vol. 12 (5) , 515-523
- https://doi.org/10.1089/152581603322448222
Abstract
Dendritic cells (DC) are professional antigen-presenting cells that are widely used in the experimental immunotherapy of cancer. For clinical use GMP-like protocols for the preparation of functionally active dendritic cells (DC) in large numbers and at high purity are needed. However, the currently available protocols have certain disadvantages. In this study we tested the generation and clinical applicability of DC from monocyte preparations produced by immunomagnetic CD14+ selection using a semiautomated clinical scale immunomagnetic column. Peripheral blood mononuclear cells (PBMC) of 10 patients with metastatic solid tumors were used. With the immunomagnetic separation, we obtained a cell suspension of high CD14+ purity (median 97.4%, range 94.9–99.0) with a high monocyte yield (median 82.3%, range 63.9–100.0). Differentiation of CD14+ cells into mature monocyte-derived DC was induced by incubation with IL-4, GM-CSF, TNF-α, PGE2, IL-1 β, and IL-6. Mature DC showed a high expression of CD83, HLA-DR, and the co-stimulatory molecules CD80 and CD86. Overall CD83+ yield was 12.1% (range 4.0–29.4). Allogeneic T stimulatory capacity could be demonstrated for all DC preparations in proliferation assays. No significant differences in marker expression or T cell stimulation was detected between fresh DC and those derived from cryopreserved immature DC. Clinical administration of autologous DC by three different parenteral routes was tolerated by all 10 patients without systemic signs of toxicity. Our results indicate that immunomagnetic isolation of CD14+ monocytes using the CliniMACS® device is a suitable method for clinical-scale generation of functional DC under GMP-grade conditions. The selection can be performed in a closed system. Therefore, immunomagnetic CD14+ selection can be seen as an alternative way to generate DC for clinical tumor vaccination protocols.Keywords
This publication has 38 references indexed in Scilit:
- Phase I study in melanoma patients of a vaccine with peptide-pulsed dendritic cells generated in vitro from CD34+ hematopoietic progenitor cellsInternational Journal of Cancer, 2000
- Dendritic Cells in Cancer ImmunotherapyAnnual Review of Immunology, 2000
- Immunobiology of Dendritic CellsAnnual Review of Immunology, 2000
- Mature dendritic cells boost functionally superior CD8+ T-cell in humans without foreign helper epitopesJournal of Clinical Investigation, 2000
- Rapid generation of broad T-cell immunity in humans after a single injection of mature dendritic cellsJournal of Clinical Investigation, 1999
- Isolation of Highly Purified Autologous and Allogeneic Peripheral CD34+ Cells Using the CliniMACS DeviceJournal of Hematotherapy, 1999
- Improved methods for the generation of dendritic cells from nonproliferating progenitors in human bloodJournal of Immunological Methods, 1996
- Large scale isolation of human blood monocytes by continuous flow centrifugation leukapheresis and counterflow centrifugation elutriation for adoptive cellular immunotherapy in cancer patientsJournal of Immunological Methods, 1994
- Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha.The Journal of Experimental Medicine, 1994
- GM-CSF and TNF-α cooperate in the generation of dendritic Langerhans cellsNature, 1992